Curosurf

Curosurf (Poractant Alfa) is a natural surfactant used for respiratory support in premature infants. This product aids in lung function and is administered via endotracheal tube.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. It works by replacing the natural surfactant in the lungs, which helps to improve breathing and lung function. This medication is administered directly into the lungs via an endotracheal tube, providing essential support for infants who are struggling with breathing difficulties.

Curosurf helps to reduce the surface tension in the lungs, allowing them to expand more easily. This can lead to improved oxygenation and reduced need for mechanical ventilation. The effects of Curosurf are typically observed soon after administration, providing immediate support to the infant's respiratory system.

Curosurf should be administered by trained healthcare professionals in a controlled medical environment. It is important to follow proper handling and storage guidelines to ensure the effectiveness of the medication. Always consult with a healthcare provider for specific instructions and precautions related to the use of Curosurf.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications or treatments the infant is receiving. This can help to avoid potential interactions and ensure the safe and effective use of Curosurf.